I
n patients with peripheral arterial disease (PAD), atherosclerotic occlusions in the blood vessels lead to tissue ischemia in the lower limbs resulting in pain while walking or even at rest. Severe PAD (critical limb ischemia) often results in tissue necrosis and limb amputation. 1 Approximately 500 to 1000 patients per million patients with PAD over 5 to 8 years develop critical limb ischemia, 2 resulting in ≈200 000 amputations in the United States alone. In the frequent setting of complete blockades in the blood vessels that supply the leg, perfusion to the limb becomes dependent on the extent of vascular remodeling from angiogenesis and arteriogenesis in the ischemic muscle. 3 Currently, no therapies can directly increase the blood flow to the ischemic muscle in patients with PAD, and new therapies are being actively sought. 4 Vascular endothelial growth factor (VEGF)-A, a potent angiogenic molecule, is upregulated in ischemic muscle, and its upregulation can contribute to tissue revascularization. [5] [6] [7] [8] The role of VEGF-A function and signaling in angiogenesis grew more complex by the discovery of alternative splicing in its eighth exon that results in the occurrence of proangiogenic VEGFxxxa (xxx for the number of amino acids) and antiangiogenic VEGFxxxb (VEGF 165 b) isoform families. [9] [10] [11] We and others have demonstrated that VEGF 165 b can impair perfusion recovery in experimental PAD. 12, 13 However, contrary to expectations, we showed that expression of VEGF 165 b impaired the extent of perfusion recovery following experimental PAD by blocking a novel vascular endothelial growth factor receptor (VEGFR)-1-STAT3 signaling in ischemic endothelial cells, but not through inhibiting VEGFR2 activation. 12 Previous publications have demonstrated that VEG-FR1 regulates the mobilization of bone marrow cells of macrophage lineage to stimulate solid tumor growth 14 ; and VEGFR1 signaling in metastasis-associated macrophages induces inflammatory signaling that promotes breast cancer metastasis. 15 In human and experimental PAD, macrophages were described to play important roles in vascular remodeling. 16, 17 Macrophages that infiltrate the ischemic muscle attain a proinflammatory, cytotoxic, and antiangiogenic M1 phenotype because of the ischemic muscle environment and aggravate tissue damage by severely hindering reparative/regenerative process and adaptive processes. 18, 19 We have recently demonstrated that increased M1-like macrophages in the distal ischemic leg (where the bulk of angiogenesis occur) decrease angiogenic remodeling. 20 So far, the macrophage-specific function of VEGFR1 activation and the downstream signaling in PAD are not known. Based on our recent report demonstrating an enhanced VEGFR1 activation post-VEGF 165 b inhibition promotes perfusion recovery in experimental PAD, 8 we investigated the mechanistic role of VEGF 165 b-VEGFR1 signaling in regulating macrophage polarization and ischemic muscle revascularization in experimental PAD.
METHODS
Expanded methods can be found in the online-only Data Supplement. The data, analytic methods, and study materials will be made available to other researchers for purposes of reproducing/replicating the procedure/results. Requests can be made to the corresponding author who manages the information.
Animal Model of Hind-Limb Ischemia
Unilateral femoral artery ligation and excision were performed on age-and sex-matched 12-to 16-week-old animals. 12, 20, 21 All animal experiments were approved and performed according to the University of Virginia Institutional Animal Care Committee Guidelines and conformed to the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health.
Human Samples
The institutional review boards at Duke University, the University of Colorado, and the University of Virginia approved the research protocols with human samples. All subjects gave informed consent.
Clinical Perspective
What Is New?
• While known functions of vascular endothelial growth factor 165 What Are the Clinical Implications?
• Therapies that can induce and sustain an M2 phenotype in ischemic muscle were not yet successful because of the reversible nature of macrophage polarization states.
• Our current work showed that targeting antiangiogenic VEGF 165 b isoforms has the translational potential to induce and sustain the M2-like macrophage phenotype in ischemic muscle to promote therapeutic angiogenesis and enhance tissue recovery.
RESULTS

Macrophage-Specific VEGF 165 b Expression Inversely Correlates With VEGFR1 Activation and Directly Correlates With M1-Like Phenotype in Ischemic Muscle
A recent study by Kikuchi et al 13 suggested that monocyte/macrophage-secreted VEGF 165 b increased circulating VEGF 165 b levels in the serum of patients with PAD and inhibited endothelial angiogenic potential by inhibiting VEGFR2 activation. To assess a quantitative correlation between VEGF 165 b levels and PAD severity, we performed VEGF 165 b ELISA (lower detection limit, 62.5 pg/mL) in plasma samples from patients with PAD and age-and sex-matched controls. We found that VEG-F 165 b levels were detectable only in ≈25% (5 of total 22 samples) of control human plasma samples (range, 13.2-25.2 pg/mL), ≈10% (2/20 samples) in intermittent claudication (18.8 pg/mL), and none (0/19 samples) in critical limb ischemia ( Figure 1A) .
We sought to determine to what extent, or whether, monocytes/macrophages contribute to circulating VEGF 165 b levels. We isolated human peripheral blood monocyte-derived macrophages (HPBMDMs) as previously described 20 and cultured them under normal or hypoxia serum starvation (HSS). HPBMDM cell lysates and conditioned media were examined for VEGF 165 Figure 1B] ).
We also isolated bone marrow-derived macrophages (BMDMs) from mice by using methods previously described. 20 Similar to the data from HPBMDMs, VEGF 165 b was not detectable from conditioned medium from BMDMs from Balb/c mice under HSS or control conditions ( Figure 1C ). However, in cell lysates, a significant increase in VEGF 165 Figure 1C] ). To confirm whether there is a difference in monocyte-versus macrophage-specific VEGF 165 b secretion pattern, we isolated bone marrow (BM) monocytes from nonischemic and ischemic Balb/c legs at day 3 post-hind-limb ischemia (HLI) and examined for VEGF 165 b secretion into culture medium. Consistent with the data from HPBMDMs and Balb/c-BMDM, VEGF 165 b was not detected in culture medium from nonischemic or ischemic leg BM ( Figure 1D ). However, in cell lysates, a significant increase in VEGF 165 b levels was observed in ischemic versus nonischemic leg BM monocytes (nonischemic leg BM, 8.8±1.7 pg/mg versus ischemic leg BM, 18.5±3.2 pg/mg, P=0.03 [ Figure 1D] ).
Knowing that ischemic monocytes/macrophages express but do not secrete VEGF 165 b protein and higher VEGF 165 b levels are linked to a poorer response to experimental PAD, 13 we hypothesized that VEGF 165 b induction serves an autocrine role in macrophages that have the ability to impair ischemic muscle tissue perfusion in PAD. To confirm our hypothesis, we next examined macrophage-specific VEGF 165 b expression in Balb/c ischemic muscle. Flow cytometry analysis (gating strategy presented in Figure I in the onlineonly Data Supplement 12, 20 ) showed significantly higher macrophage-specific VEGF 165 ) populations and examined the extent of VEGFR1 activation within these populations. 12 Flow cytometry analysis showed that, whereas VEGF 165 b +ve macrophages in ischemic muscle have significantly lower VEGFR1 activation (≈30×) versus nonischemic (P=0.001, Figure 1G ), VEGF 165 b -ve macrophages showed no significant differences in VEGFR1 activation 
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versus nonischemic ( Figure 1H ). Because VEGFR1 activity has been associated with changes in macrophage phenotype, 23 we hypothesized that VEGF 165 b inhibits VEGFR1 activation to induce a proinflammatory phenotype. Consistent with our hypothesis, increased VEGF 165 b expression in macrophages correlated with a significant increase (≈6×) in M1-like phenotype 24 Figure 1K ). We next performed immunofluorescence analysis to determine differences in CD206 + (M2-like) and CD80 + (M1-like) macrophages in normal and PAD muscle biopsies. A significant increase in total macrophages (CD68 + , a pan-macrophage marker) was observed (≈2×, normal 16±2.1 versus PAD 33.8±1.6) in PAD muscle biopsies versus normal ( Figure 1L ). Subsequent analysis of CD80 + and CD206 + macrophages in total CD68 + macrophages showed a significant increase (≈3×) in CD80 + macrophages in PAD muscle versus normal (normal 9±3.1 versus PAD 27.5±2.4, P=0.0004, Figure 1M ), but no significant difference in CD206 + macrophages in total CD68 + macrophages (normal 7.7±2.9 versus PAD 12.7±1.0, Figure 1N ). Immunostaining with CD163 + (M2 marker) also showed no significant difference in CD163 + macrophages between PAD muscle versus normal ( Figure III in the online-only Data Supplement).
We next quantified CD133 + cells to determine whether immature progenitor cells contributed to changes in macrophage subsets in PAD muscle biopsies. Although total CD133 + cells are significantly lower in PAD muscle versus normal (indicating that increased total or M1-like macrophages are not attributable to 
CD68
+ cells was observed between PAD muscle versus normal (data not shown).
We have previously shown that higher VEGF 165 b protein in PAD muscle biopsies correlated with decreased VEGFR1 activation, 12 and our current data show that VEGF 165 b induction correlates with increased M1-like phenotype in PAD muscle biopsies. Hence, we conclude that VEGF 165 b induction in ischemic muscle decreases macrophage-specific VEGFR1 activation to induce an M1-like phenotype in patients with PAD. Figure 2G ). Thrombospondin-1 is a known antiangiogenic molecule that has been shown to induce M1-like macrophages. 26 We next determined whether increased M2-like macrophages post-VEGF 165 b inhibition are attributable to decreased thrombospondin-1 levels. Immunoblot analysis showed no significant difference in thrombospondin-1 expression, either in ischemic muscle or in HSS BMDMs treat- 
VEGF 165 b-Expressing M1-Like Macrophages Impair Perfusion in Preclinical PAD in a Paracrine Manner
Because C57Bl6 mice exhibit a striking ability to favorably recover from HLI (ie, a better recovery mouse strain than the Balb/c mouse strain in preclinical PAD), 27, 28 we examined whether VEGF 165 b-expressing macrophages can impair angiogenesis and perfusion recovery in C57Bl/6 ischemic muscle. First, we collected conditioned medium from (1) BMDMs transfected with negative plasmid or VEGF 165 b-expressing plasmid (transfection efficiency presented in Figure  II in the online-only Data Supplement) and (2) HSSchallenged BMDMs treated with IgG or VEGF 165 b-Ab in vitro. Although conditioned medium from C57Bl/6-BMDM transfected with VEGF 165 b-expressing plasmid significantly decreased capillary-like tube formation on growth factor-reduced Matrigel (GFRM) versus C57Bl/6-BMDM transfected with negative plasmid (P<0.05, Figure 3A ), conditioned medium from HSSchallenged C57Bl/6-BMDM treated with VEGF 165 b-Ab increased capillary-like tube formation on GFRM versus IgG (≈3×, P<0.05 [ Figure 3B ]). We next adoptively transferred C57Bl6-BMDM transfected with control or VEGF 165 b-expressing plasmid into C57Bl/6 ischemic muscle immediately after HLI and examined angiogenesis and perfusion recovery. Laser Doppler imaging showed a significant decrease in the perfusion recovery in the ischemic muscle treated with VEGF 165 b-expressing macrophages versus 
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Immunohistochemistry showed a significant decrease in CD31 + (endothelial) cells in the ischemic muscle treated with VEGF 165 b-expressing BMDM versus control ( Figure 3D ). These results indicated that increased n=6. Unpaired t test to determine statistical significance. C, Laser Doppler perfusion imaging of C57Bl/6 ischemic muscle treated with BMDM transfected with negative plasmid or VEGF 165 b-expressing plasmid. n≥5. Repeated-measures ANOVA with Dunnett multiple test correction was used to determine statistical significance. *P<0.05 was considered significant from day 0; #P<0.05 was considered significant between groups at that specific day (unpaired t test was used to determine statistical significance). D, CD31 immunostaining in ischemic muscle treated with BMDM transfected with negative plasmid or VEGF 165 
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are embryonic lethal) backcrossed to Balb/c background that
VEGFR1 +/-Macrophages Impair Perfusion Versus VEGFR1 +/+ Macrophages in Preclinical PAD
Because VEGF 165 b induced VEGFR1-dependent M1-like polarization, we next examined the role of macrophage-specific VEGFR1 in regulating perfusion recovery in experimental PAD. Quantitative polymerase chain reaction (qPCR) analysis showed that, although HSS significantly induced VEGFR1 expression in VEGFR1 +/+ BMDM versus control (≈5.5×), no significant difference in VEGFR1 expression was observed in VEGFR1 +/-under HSS versus control ( Figure X in Figure 5A ), indicating that VEGFR1 plays an important role in regulating macrophage polarization. Functional analysis of VEGFR1 +/-BMDM showed that conditioned medium from normal VEGFR1 +/-BMDMs did not change endothelial capillary-like tube formation on GFRM (Figure 5B) ; however, HSS-VEGFR1 +/-BMDMs significantly decreased endothelial capillary-like tube formation on GFRM versus conditioned medium from HSS-VEGFR1 +/+ BMDMs (P=0.02, Figure 5C ). After confirming that HSS induces M1-like phenotype in VEGFR1 +/-BMDM that can inhibit endothelial angiogenic potential, in a paracrine manner, in vitro, we next examined their functional role in regulating perfusion in vivo. Figure 5D] ). Immunohistochemistry showed a significant decrease in vascular density (CD31 + ) in ischemic muscle that received VEGFR1 +/-BMDM versus VEGFR1 +/+ BMDM (Figure 5E ). These data indicated that VEGF 165 b inhibition of VEGFR1 plays a role in regulating macrophage paracrine effects on ischemic vasculature.
VEGFR1-STAT3 Interactions Regulate Macrophage Phenotype in Preclinical PAD
We next wanted to determine the signaling processes/ intermediates downstream of VEGFR1 Y1333 activation that play a role in macrophage polarization. We have We next examined the causal role of VEGFR1 in regulating STAT3 activation to modulate macrophage polarization using VEGFR1 +/-mice. Flow cytometry analysis showed a significant decrease in STAT3 activation in total macrophages from VEGFR1 +/-ischemic muscle (IGA ≈2×, P<0.03 [ Figure 6D ]) versus VEGFR1 +/+ . A significant decrease in Arg-1 + macrophages in VEGFR1 +/-ischemic muscle was associated with decreased STAT3 activation (IGA ≈10×, P=0.001 [ Figure 6E ]). A significant increase in CD80 high macrophages in VEGFR1 +/-ischemic muscle was associated with decreased STAT3 activation (IGA ≈3×, P=0.01 [ Figure 6F ]) when versus VEGFR1 +/+ . Based on our recent data that show VEGFR1 when activated by VEGF 165 a interacts with STAT3 to induce STAT3 activation in endothelial cells, 12 +/-BMDM. n≥5. Repeated-measures ANOVA with Dunnett multiple test correction was used to determine statistical significance. *P<0.05 is considered significant from day 0; #P<0.05 is considered significant between groups at that specific day (unpaired t test was used to determine statistical significance). E, CD31 immunostaining in WT ischemic muscle treated with VEGFR1 +/+ or VEGFR1 +/-BMDM. n≥5. Unpaired t test was used to determine statistical significance. *P<0.05 is considered significant. BMDM indicates bone marrow-derived macrophage; Con, Control; HPRT, Hypoxanthine Phosphoribosyltransferase; iNos, inducible nitric oxide synthase; Nor, normal; qPCR, quantitative polymerase chain reaction; VEGFR1, vascular endothelial growth factor receptor 1; and WT, wild type.
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S100A8/S100A9 Downstream of VEGFR1 Regulates Macrophage Polarization
Unlike VEGFR2, information on genes that regulate VEGFR1 downstream processes is limited. 30, 31 Hence, to identify the VEGFR1 downstream signaling genes that regulate macrophage polarization, we performed RNA-Seq analysis of HSS-challenged VEGFR1 +/-and VEGFR1 +/+ BMDMs (Tables I and II in the online-only Data Supplement). Volcano plots, principal component analysis, 32 and hallmark pathway analysis 33 (Gene Set Enrichment Analysis ) of the RNA-Seq data are presented in Figure XII in the online-only Data Supplement. RNA-Seq analysis showed that S100A8 and S100A9, members of the S100 family that regulates intracellular calcium levels, 34, 35 are significantly upregulated in HSSchallenged VEGFR1 +/-BMDM versus VEGFR1 +/+ (within top 5 genes, adjusted P value (q)<0.05, Figure XII in the online-only Data Supplement, Table I in the onlineonly Data Supplement). qPCR analysis of S100A8 and S100A9 in normal and HSS-challenged VEGFR1 +/+ and VEGFR1 +/-BMDM showed no significant difference in S100A8 or S100A9 expression between normal VEG-FR1 +/-and VEGFR1 +/+ BMDM, but a significant increase in HSS-VEGFR1 +/-BMDM versus HSS-VEGFR1 +/+ BMDM confirming the RNA-Seq data ( Figure 7A and 7B) . Furthermore, a significant increase in S100A8 and S100A9 expression was also observed in VEGFR1 +/-ischemic muscle ( Figure 7C and 7D) and HSS VEGFR1 +/-skeletal muscle endothelial cells ( Figure XIII in the online-only Data Supplement) versus respective controls. No significant difference in S100A8 and S100A9 expression was observed between VEGFR1 +/+ versus VEGFR1 +/-nonisch- ) nonischemic (NGA), and ischemic gastrocnemius muscle (IGA). n=5. One-way ANOVA with Bonferroni select-pair comparison was used to determine statistical significance. E through H, qPCR analysis of arginase-1 (Arg-1) and inducible nitric oxide synthase (iNos) expression in macrophages (Raw264.7) transfected with S100A8 (E and F) or S100A9 (G and H) under normal or HSS conditions. n=6. Unpaired t test was used to determine statistical significance. I and J, qPCR analysis Arg-1:iNos expression in S100A8-(I and K) or S100A9-(J and L) transfected macrophages treated with BAPTA-AM under normal or HSS conditions. n=6. Unpaired t test was used to determine statistical significance. M and N, In vitro angiogenesis assay of endothelial cells treated with conditioned medium (CM) from normal (M) or HSS-challenged (N) macrophages transfected with control plasmid (Neg Pld), S100A8 plasmid (S100A8 Pld), or S100A9 plasmid (S100A9 Pld). n=4. One-way ANOVA with Dunnett multiple test correction was used to determine statistical significance. *P<0.05 is considered significant. BAPTA-AM indicates 2-bis (2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid tetrakis(acetoxymethyl ester); DMSO, dimethyl sulfoxide; HPRT, Hypoxanthine Phosphoribosyltransferase; HSS, hypoxia serum starvation; Nor, normal; qPCR, quantitative polymerase chain reaction; and VEGFR1, vascular endothelial growth factor receptor 1.
ORIGINAL RESEARCH ARTICLE
emic muscle ( Figure 7C and 7D) We next examined S100A8 and S100A9 function in regulating macrophage polarization and angiogenesis in vitro. qPCR analysis of Arg-1 and iNos in macrophages overexpressing S100A8 or S100A9 showed a significant decrease in Arg-1 expression (S100A8: normal [ Figure 7E through 7H) . The transfection efficacy of S100A8 is presented in Figure XIV in the online-only Data Supplement. Cycle threshold values of S100A9 in negative-plasmid transfected macrophages (Raw264.7) was higher than 50 cycles, and S100A9 plasmid transfection decreased the Cycle threshold values to a mean of 22±0.17.
Because S100A8 and S100A9 were shown to induce calcium influx in neutrophils, 36 we next examined whether calcium influx attributable to increased S100A8 and S100A9 expression drives the M1-like phenotype. To confirm, we overexpressed S100A8 or S100A9 in macrophages and treated them with DMSO BAPTA-AM (1,2-bis (2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid tetrakis(acetoxymethyl ester)), a cell-permeable calcium chelator 37 under normal or HSS conditions. It is interesting to note that BAPTA-AM induced greater Arg1:iNos expression in macrophages under normal conditions, but no significant difference in Arg1:iNos expression was observed under HSS conditions ( Figure  XV in the online-only Data Supplement). However, BAP-TA-AM not only blocked S100A8-and S100A9-induced M1-like phenotype but also promoted an M2-like phenotype both under normal (Arg1:iNos: S100A8≈1× [P=0.03], S100A9≈3× [P=0.0003], Figure 7I and 7J) and HSS (Arg1:iNos: S100A8 [P=0.03], S100A9 [P=0.01], Figure 7K and 7L) conditions. These data suggested that, although HSS induces an M1-like phenotype, this phenotype may not be attributable to increased calcium levels, but S100A8-and S100A9-induced M1-like phenotype is via increased calcium influx.
We next examined the role of S100A8 and S100A9 in endothelial cells. Overexpressing either S100A8 or S100A9 showed no significant difference in capillarylike tube formation on GFRM in vitro ( Figure XVI in the online-only Data Supplement). However, conditioned medium from macrophages transfected with S100A8 or S100A9 under normal and HSS conditions significantly decreased endothelial tube-like formation on GFRM ( Figure 7M and 7N) . These data suggested that increased S100A8 and S100A9 expression in macrophages inhibits endothelial angiogenic potential in a paracrine manner.
Because earlier reports have indicated that toll-like receptor signaling regulates S100A8 expression via the STAT3 pathway in macrophages, 38 we next examined whether STAT3 regulates S100A8 in macrophages under HSS conditions. qPCR analysis of S100A8 in macrophages treated with or without STAT3 inhibitor (100 μmol/L) showed no significant difference in S100A8 expression ( Figure XVII in the online-only Data Supplement), indicating that in macrophages, STAT3 is not a regulator of S100A8. Furthermore, our data also indicate that VEGFR1 activation induces distinct signaling independent of STAT3 activation to inhibit S100A8 and S100A9 expression in macrophages.
VEGF 165 b Regulates S100A8/S100A9 Expression in Preclinical PAD
We next wanted to obtain direct evidence of VEGF 165 b in regulating macrophage-specific S100A8 and S100A9 expression. Because S100A8 and S100A9 expression is significantly higher in ischemic versus nonischemic muscle ( Figure Figure 8B ) specific S100A8/ S100A9 expression versus IgG. Furthermore, gating on S100A8/S100A9 + macrophages showed that VEGF 165 b inhibition significantly decreased S100A8/S100A9 + CD80
+ macrophages ( Figure 8C ) in ischemic muscle versus IgG. No significant difference in S100A8/S100A9 + Arg-1 + macrophages was observed. To confirm the in vivo data, we next overexpressed S100A8 or S100A9 in macrophages and treated them with IgG or VEGF 165 b-Ab under normal or HSS conditions. qPCR analysis showed that VEGF 165 b inhibition significantly induced Arg-1 expression (S100A8: Nor ≈6×, HSS ≈9×; S100A9: Nor ≈6.5×, HSS≈14.5× [ Figure 8D] ) in macrophages both under normal and HSS conditions. No significant difference in iNos expression was observed between IgG-or VEGF 165 b-Ab-treated S100A8 or S100A9 transfected macrophages under normal or HSS conditions ( Figure 8E ). These data indicated that VEGFR1 activation post-VEGF 165 b inhibition decreases S100A8/S100A9 expression to induce M2-like polarization in preclinical PAD. A schematic of the VEGF 165 b signaling that regulates macrophage polarization in ischemic muscle is presented in Figure 8F .
DISCUSSION
The results of our study demonstrate for the first time that VEGF 165 b, a previously unrecognized splice variant 165 b isoform expression in macrophages directly and competitively inhibits VEGFR1-S100A8/S100A9 signaling to induce an M1-like phenotype that inhibits ischemic muscle angiogenesis and perfusion recovery in PAD.
Our understanding of the function of the alternatively spliced VEGF 165 b isoform is expanding, but studies to date have largely focused on its role in blocking VEGFR2 activation in endothelial cells. Our current data show that, in ischemic macrophages, VEGF 165 b induces an autocrine effect that inhibits VEGFR1 Y1333 activation, which results in an M1-like phenotype that in turn exerts a paracrine effect on hypoxia-dependent angiogenesis. We have recently shown that VEGF 165 b exhibits differential effects on VEGFR1 and VEGFR2 activation, ie, it functions as an inhibitory isoform for VEGFR1 Y1333 and functions as an activator of VEGFR2 Y1175 in endothelial cells 12 (contrary to the existing paradigm that VEGF 165 b largely functions as a competitive blocker of VEGF 165 a-induced VEGFR2 activation 9, 11, 30, [39] [40] [41] [42] ). Although VEGFR2 expression is largely confined to endothelial cells, VEGFR1 is expressed on nonendothelial cell types, 43, 44 including progenitor cells, macrophages, and inflammatory cells, suggesting that the function of VEGF 165 b may well extend beyond endothelial cells. However, unlike the extensive literature that exists on the VEGFR2 signaling networks, far less is known of VEGFR1 signaling and function in cardiovascular diseases. 43, 45 Our finding of an increased M1-like phenotype with VEGFR1 inhibition suggested that VEGF 165 b may function as more than an inert blocker. 
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We have previously shown that VEGF 165 b modulates VEGFR1-STAT3 activation in endothelial cells to increase angiogenesis. However, in macrophages, VEGF 165 b regulates not only VEGFR1-STAT3 signaling but also VEGFR1-S100A8/S100A9 signaling to regulate an M1-like phenotype. We identified S100A8/S100A9 as downstream signaling intermediates of VEGFR1 by RNA-Seq analysis of HSS VEGFR1 +/+ BMDM versus VEGFR1 +/-BMDM. We used HSS VEGFR1 +/+ and HSS VEGFR1 +/-BMDM because no difference in VEGFR1 expression was observed between VEGFR1
+/+ and VEGFR1 +/-BMDM under normal conditions. Even though we identified S100A8/S100A9 downstream of VEGFR1 in macrophages, we observed significantly higher S100A8/S100A9 levels in HSS VEG-FR1 +/-endothelial cells versus HSS VEGFR1 +/+ endothelial cells, indicating that VEGFR1 regulates S100A8/ S100A9 expression in endothelial cells also. Based on the limited amount of literature that exists on VEGFR1 signaling intermediates, these data should advance the study of VEGFR1 biology.
Recent literature has shown that STAT3 can bind to the promoter of S100A8 in macrophages to induce S100A8 expression 38 ; and increased S100A8 expression can induce STAT3 levels in lung injury models by lipopolysaccharide or cytosine-p-guanine-DNA, 46 indicating a potentially positive feedback loop between S100A8 and STAT3 to regulate macrophage phenotype. However, in culture, STAT3 inhibition did not change S100A8 levels, indicating that STAT3 regulation of S100A8 is cell-and context-dependent. These data expanded our recent findings and showed that novel VEGFR1-dependent but STAT3-independent signaling regulates S100A8/S100A9 expression in macrophages that converge on regulating an M2-like phenotype. These data demonstrate that removal of the VEGF 165 b inhibitory effect on VEGFR1 regulates the M2-like phenotype in (at least) 2 distinct ways. One involves VEGFR1 activation of STAT3; another signaling involves VEGFR1 inhibition of S100A8/S100A9, which converges on inducing an M2-like phenotype that promotes angiogenesis and tissue recovery in distal ischemic muscle. Additional work will be required to delineate the molecular signaling that connects VEGFR1-S100A8/S100A9 signaling.
It is interesting to note that, although S100A8 or S100A9 overexpression did not directly modulate endothelial angiogenic potential under normal or HSS conditions, conditioned medium from S100A8-or S100A9-transfected macrophages significantly decreased endothelial angiogenic potential. Even though S100A8 or S100A9 did not directly modulate endothelial angiogenic potential in vitro, it is possible that S100A8/S100A9 can modulate other endothelial properties, such as vascular integrity/permeability, adhesion molecule expression, and immune cell migration. 47, 48 Furthermore, whereas conditioned medium from VEGF 165 b transfected and HSS-VEGFR1 +/-BMDM significantly decreased endothelial angiogenic capacity, conditioned medium from BMDM treated with VEGF 165 bAb significantly induced endothelial angiogenic capacity, indicating that increased VEGF 165 b expression in ischemic macrophages inhibits angiogenesis in a paracrine manner. In addition, adoptive transfer of VEGF 165 b-transfected BMDM and VEGFR1 +/-BMDM significantly decreased angiogenesis and perfusion in the ischemic muscle in vivo, indicating that macrophage-specific VEGFR1 signaling plays a major role in regulating PAD muscle perfusion recovery. Consistent with our murine findings, our recently published human data from PAD and control (age-and sex-matched) biopsies showed that greater VEGF 165 b binding to VEGFR1 correlated with decreased VEGFR1 activation 12 ; and, in our current work, we show that VEGF 165 b induction correlated with increased CD80 + macrophages in human PAD. These data showed that VEGF 165 b inhibits VEGFR1 to induce an M1-like phenotype in human PAD. However, the markers used to distinguish M1 versus M2 macrophages 24 are not binary. Although flow cytometry analysis will provide a better delineation of these cell populations with a more restricted marker expression, muscle availability from human muscle biopsies limited us for studies such as double-immunofluorescence analysis of CD68 and CD80 or CD206.
Kikuchi et al 13 have previously shown that VEGF 165 b levels are significantly higher in the serum of PAD versus healthy patients by Western blot analysis. Serum preparation involves platelet activation to form a blood clot, and it is possible that VEGF 165 b is released by circulating monocytes or perhaps activated platelets in this process in patients with PAD. Furthermore, HSS macrophages expressed higher VEGF 165 b levels, but this remains cellassociated and is not secreted, suggesting an autocrine effect. Unlike the freely circulating VEGF 121 a isoform, VEGF 165 a is predominantly membrane-bound, and, indeed, Guzmán-Hernández et al 49 showed that VEGF 165 a is prominently present on the outer surface of the cells. The membrane-binding properties of VEGF 165 a are attributable to the heparin-binding sites in exon-7, which is the same in VEGF 165 b isoforms. As such, we predict that VEGF 165 b, similar to VEGF 165 a, is inherently membrane-bound. Whether and to what extent the 6-amino acid switch in VEGF 165 b isoforms confers increased membrane-binding properties resulting in decreased secretion is not clear. Such studies will advance our understanding of the mechanism of VEGF 165 b action.
The novelty of these findings on VEGF 165 b and its role on macrophages are relevant, not only for PAD, but also across other human cardiovascular diseases. The online-only Data Supplement is available with this article at https://www. ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.118.034165.
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